Merck & Co.
AWARDS
NEWS
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as tree or grass pollen, and each person has their own set of problematic allergens.
It doesn’t happen that often, but Merck’s checkpoint inhibitor Keytruda received a rejection from the U.S. Food and Drug Administration.
The U.S. Food and Drug Administration has a busy week planned for drug review. Here’s a look at this week’s schedule.
It was a very busy week for clinical trial news. Here’s a look.
Screening using EMR data could help with early identification of Alzheimer’s disease risk
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) proved itself effective in yet another cancer indication.
JOBS
IN THE PRESS